How Genome Editing is Revolutionizing Medicine

Contents

1 Introduction

2 State-of-the-art Gene Editing

2.1 PAM sequence

2.2 Type II CRISPR-Cas System - Cas9 variants and orthologs

2.2.1 dCas9

2.2.2 eSpCas9

2.2.3 SpCas9-HF1

2.2.4 HypaCas9

2.2.5 xCas9

2.2.6 Cas9 Nickases

2.2.7 Remarkable SpCas9 Orthologs

2.2.8 Base editing

2.2.9 Prime editing

2.3 Type V CRISPR-Cas System - Diagnostic tools

2.3.1 Cas12a, Cas12b

2.4 Type VI CRISPR-Cas System - RNA targeting

2.4.1 Cas13a

2.4.2 CasRx

2.5 Transfection methods

2.5.1 Non-viral

2.5.2 Viral

3 Gene Editing and Treatment of Diseases

3.1 Hemoglobinopathies

3.1.1 CRISPR-correction of sickle cell disease

3.1.2 Reactivation of Fetal Hemoglobin Production

3.2 Cystic fibrosis

3.2.1 Functional repair of the CFTR gene

3.2.2 CFTR repair using Adenine Base Editors

3.3 Duchenne muscular dystrophy (DMD)

3.3.1 CRISPR-Cas9 restores functional dystrophin in mice

3.3.2 Long-term evaluation of Dystrophin restoration in mice

3.4 Treatment of Human Immunodeficiency Virus

3.4.1 Genome editing of HIV co-receptors CCR5 and CXCR4

3.4.2 HIV elimination using ART and CRISPR-Cas9

3.5 Cancer immunotherapy

3.5.1 Editing Primary Human Natural Killer Cells

3.5.2 Creating enhanced CAR T Cells using CRISPR-Cas9

3.5.3 Creating universal CAR T cells with CRISPR-Cas9

4 Gene Editing for Drug Development

4.1 Glycoengineering

4.2 Prolonged cultivation

4.3 Elimination of host cell protein impurities

4.4 Rapid adaptation cells

4.5 Enhanced protein production

5 Gene Editing Tools for Diagnostics

5.1 Diagnostic CRISPR endonucleases

5.1.1 Cas12a, Cas12b

5.1.2 Advanced endonucleases for diagnostic

5.1.3 Cas13a

5.2 SHERLOCK

5.2.1 SARS-CoV-2 Detection using SHERLOCK

5.3 DETECTR

5.3.1 SARS-CoV-2 Detection using DETECTR

5.4 CRISPR targeting of drug-resistant bacteria

5.4.1 Targeting pathogenic and drug-resistant bacteria

6 Challenges and Obstacles

6.1 Off-target effects and carcinogenesis

6.2 Delivery of the CRISPR-Cas system

6.3 Immune responses against CRISPR-Cas

7 Prospect

Research Objectives and Focus Areas

The primary objective of this thesis is to provide a comprehensive overview of modern gene editing, specifically focusing on the CRISPR-Cas system's current applications in medicine, drug development, and diagnostics. The work aims to summarize recent scientific literature to assess how CRISPR technologies facilitate the treatment of hereditary diseases, viral infections, and cancer, while also examining the challenges and future prospects of these tools in clinical practice.

• Mechanisms and variants of CRISPR-Cas systems (Class 2).
• Clinical applications in treating monogenic and infectious diseases.
• Optimizing therapeutic efficacy through cell line engineering.
• Advancements in CRISPR-based diagnostic tools for infectious diseases.
• Safety, off-target effects, and delivery challenges in clinical translation.

Excerpt from the Book

Chapter Summaries

1 Introduction: Provides an overview of CRISPR as a programmable genome editing tool and its rapid evolution from an ancient bacterial immune system.

2 State-of-the-art Gene Editing: Details various CRISPR-Cas systems, focusing on class 2 variants, endonuclease mechanisms, and delivery strategies.

3 Gene Editing and Treatment of Diseases: Explores therapeutic applications for monogenic disorders, HIV, and cancer immunotherapy.

4 Gene Editing for Drug Development: Analyzes the use of CRISPR for optimizing cell lines in pharmaceutical production, focusing on glycoengineering and yield.

5 Gene Editing Tools for Diagnostics: Describes CRISPR-based diagnostic platforms like SHERLOCK and DETECTR for detecting viral pathogens.

6 Challenges and Obstacles: Discusses technical and clinical hurdles, including off-target effects, delivery issues, and immune responses.

7 Prospect: Concludes with an outlook on the future potential of CRISPR in diagnostics and therapeutics, emphasizing the need for continued safety research.

Keywords

CRISPR, Cas9, Gene Editing, Clinical Therapy, Drug Development, Diagnostics, SARS-CoV-2, Immunotherapy, Delivery Systems, Off-target Effects, Inherited Diseases, CHO Cells, Biotechnology, Genome Engineering, Molecular Biology

Frequently Asked Questions

What is the core focus of this thesis?

The work provides a summary of modern gene editing practices using CRISPR-Cas systems, specifically highlighting its role in medicine, drug development, and diagnostics.

What are the primary fields of application discussed?

The central thematic fields include the treatment of hereditary diseases, cancer immunotherapy, viral infection research, and pharmaceutical cell line optimization.

What is the main objective or research goal?

The goal is to provide a comprehensive, up-to-date overview of current CRISPR applications and challenges to support the rapid evaluation of new developments in the field.

Which scientific methods are primarily analyzed?

The thesis analyzes Class 2 CRISPR-Cas systems, including various Cas9 variants, Cas12a/b, and Cas13/CasRx nucleases, as well as different viral and non-viral delivery vectors.

What does the main body of the work cover?

It covers the mechanism of gene editing, specific clinical case studies for monogenic and infectious diseases, technical methods for enhancing drug manufacturing, and advanced diagnostic technologies.

Which keywords best characterize this work?

Key terms include CRISPR, Gene Editing, Clinical Therapy, Diagnostics, Immunotherapy, Drug Development, and Delivery Systems.

How is CRISPR used in drug development?

CRISPR is used to engineer CHO cell lines to improve protein production, glycoengineering, and adaptation to serum-free media, thereby increasing manufacturing efficiency.

What are the major challenges addressed in the text?

The main hurdles identified are off-target effects, chromosomal instability, the difficulty of efficient delivery, and potential human immune responses against CRISPR components.